Phase 2 N=30 Treatment

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Chronic Inducible Urticaria

Bottom Line

View on ClinicalTrials.gov: NCT06603220 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Safety and Tolerability — 3; 7 Participants with a TEAE

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Oral EVO756 300 mg QD (Drug); Oral EVO756 50 mg BID (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Evommune, Inc.
Primary completion: May 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Safety and Tolerability	3; 7	—
SECONDARY Change in Total Fric Score (TFS)	-1.4; -1.5	—
SECONDARY Change in Pruritus Severity at the Provocation Test Site	-2.4; -2.1	—

Summary

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Eligibility Criteria

Inclusion Criteria

Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
Positive response following provocation using the TempTest or FricTest at Screening and Day 1.

Exclusion Criteria

History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
Concurrent use of certain medications, including antihistamines.
Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06603220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.